Table 2 Survival influence of VIRMA in various cancers
From: Role of m6A methyltransferase component VIRMA in multiple human cancers (Review)
Cancer type | Sample size | Survival influence | References |
|---|---|---|---|
Breast cancer | low-VIRMA (n = 528); high-VIRMA (n = 528) | Worse OS | [20] |
low-VIRMA (n = 598); high-VIRMA (n = 472) | Worse OS | [42] | |
low-VIRMA (n = 611); high-VIRMA (n = 457) | Worse RFS | [42] | |
TCGA | Worse OS | [41] | |
Liver cancer | 70 HCC patients | Worse OS and DFS | [29] |
low-VIRMA (n = 182); high-VIRMA (n = 182) | Worse OS | [43] | |
374 HCC and 50 normal tissues from TCGA; 243 HCC and 202 normal tissues from ICGC | Worse OS | [45] | |
Kidney cancer | 897 samples from 895 patients | Worse OS and DFS | [44] |
Kidney renal clear cell carcinoma | TCGA | Better OS | [41] |
Kidney renal papillary cell carcinoma | 289 kidney renal papillary cell carcinoma and 32 normal kidney samples from the TCGA database | Better OS and DFS | [49] |
Prostate cancer | TCGA + GTEx, 492 prostate adenocarcinoma and 152 adjacent normal specimens | Worse DFS | [58] |
Gliomas | 309 glioma patients from CGGA and 595 glioma patients from TCGA | Worse OS | [75] |
Ovarian cancer | 370 ovarian cancer tissues and 88 normal tissues from TCGA | Worse OS | [51] |
Papillary thyroid carcinoma | 499 tumor tissues and 58 normal thyroid carcinoma | Better OS | [52] |